Stereotactic Body Radiotherapy for the Management of Prostate Cancer Local Recurrences

Stereotactic Body Radiotherapy for the Management of Prostate Cancer Local Recurrences - CHANCES

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00030837

Enrollment

Registered

2022-12-06

Start date

2023-02-02

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C61

Interventions

Group 1: Single-fraction stereotactic body radiotherapy

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Histologically confirmed prostate cancer in the past medical history, radiographically verified local recurrence, status post prostatectomy and/or external beam radiotherapy

Exclusion criteria

Exclusion criteria: Lymph node metastases or distant metastases in the past medical history

Design outcomes

Primary

Measure	Time frame
Cumulative incidence of new acute treatment-related genitourinary and gastrointestinal toxic effects = grade 2 according to CTCAE v5.0 three months after SBRT.	—

Secondary

Measure	Time frame
Time to new androgen deprivation therapy, time to first metastasis, freedom from biochemical recurrence, quality of life per EPIC-26 and SF-12.	—

Countries

Germany

Contacts

Public ContactFelix Ehret

Charité - Universitätsmedizin Berlin

felix.ehret@charite.de+49 30 450 557 088

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026